TY - JOUR
T1 - Body fluid biomarkers in multiple sclerosis
AU - Comabella, Manuel
AU - Montalban, Xavier
PY - 2014/1
Y1 - 2014/1
N2 - Biomarkers can be thought of as multifaceted indicators of healthy status or of pathological disorders. The study of multiple sclerosis can benefit from the use of biomarkers because of the disease's inherent heterogeneity. Biomarkers in multiple sclerosis might assist with diagnosis, prediction of disease course, or identification of response outcome to treatments. Despite the need for biomarkers and extensife research to identify them, validation and clinical application of biomarkers is still an unmet need in multiple sclerosis, and large gaps remain between exploratory biomarkers proposed in many studies, validated biomarkers, and biomarkers that are integrated into routine clinical practice.
AB - Biomarkers can be thought of as multifaceted indicators of healthy status or of pathological disorders. The study of multiple sclerosis can benefit from the use of biomarkers because of the disease's inherent heterogeneity. Biomarkers in multiple sclerosis might assist with diagnosis, prediction of disease course, or identification of response outcome to treatments. Despite the need for biomarkers and extensife research to identify them, validation and clinical application of biomarkers is still an unmet need in multiple sclerosis, and large gaps remain between exploratory biomarkers proposed in many studies, validated biomarkers, and biomarkers that are integrated into routine clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84892176685&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(13)70233-3
DO - 10.1016/S1474-4422(13)70233-3
M3 - Review article
C2 - 24331797
AN - SCOPUS:84892176685
SN - 1474-4422
VL - 13
SP - 113
EP - 126
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 1
ER -